Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sufentanil + ropivacaine is a combination of a potent synthetic opioid analgesic and a long-acting amide-type local anesthetic. It is commonly used for epidural labor analgesia to provide effective pain relief during childbirth. Sufentanil acts as a highly selective agonist at the mu-opioid receptor, providing systemic and neuraxial analgesia. Ropivacaine works by reversibly blocking sodium channels in nerve fibers, inhibiting the conduction of nerve impulses. In clinical research conducted by Peking University First Hospital, this combination is often utilized as a standard of care comparator for evaluating novel analgesic regimens like dexmedetomidine-esketamine-ropivacaine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sufentanil + ropivacaine.